SUPERNUS PHARMACEUTICALS INC
For the period ended Sep 30, 2024. Filed Nov 4, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 4, 2024
SUPN$28.75+4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Unaudited Condensed Consolidated Financial Statements
Condensed Consolidated Balance Sheets
(in thousands, except share data)
| September 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| (unaudited) | ||
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $31,673 | $75,054 |
| Marketable securities | 371,537 | 179,820 |
| Accounts receivable, net | 145,408 | 144,155 |
| Inventories, net | 63,981 | 77,408 |
| Prepaid expenses and other current assets | 27,404 | 16,676 |
| Total current assets | 640,003 | 493,113 |
| Long-term marketable securities | — | 16,617 |
| Property and equipment, net | 11,876 | 13,530 |
| Intangible assets, net | 540,156 | 599,889 |
| Goodwill | 117,019 | 117,019 |
| Other assets | 33,647 | 37,505 |
| Total assets | $1,342,701 | $1,277,673 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable and accrued liabilities | $75,803 | $79,569 |
| Accrued product returns and rebates | 169,124 | 154,274 |
| Contingent consideration, current portion | 46,581 | 52,070 |
| Other current liabilities | — | 4,283 |
| Total current liabilities | 291,508 | 290,196 |
| Contingent consideration, long-term | 403 | 1,380 |
| Operating lease liabilities, long-term | 28,926 | 33,196 |
| Deferred income tax liabilities, net | 7,364 | 24,963 |
| Other liabilities | 7,350 | 6,422 |
| Total liabilities | 335,551 | 356,157 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ equity | ||
| Common stock, $0.001 par value; 130,000,000 shares authorized; 55,219,273 and 54,723,356 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 55 | 55 |
| Additional paid-in capital | 465,919 | 439,493 |
| Accumulated other comprehensive earnings (loss), net of tax | 78 | (593) |
| Retained earnings | 541,098 | 482,561 |
| Total stockholders’ equity | 1,007,150 | 921,516 |
| Total liabilities and stockholders’ equity | $1,342,701 | $1,277,673 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.